Profilo
Yves Dudal is the founder of Envolure SAS.
He is currently the Chief Executive Officer & Director at Perseo pharma AG and also holds the position of Director at INOFEA AG.
Posizioni attive di Yves Dudal
Società | Posizione | Inizio |
---|---|---|
Envolure SAS
Envolure SAS Medical SpecialtiesHealth Technology Envolure SAS designs, develops and commercializes laboratory kits. It offers its products for the diagnostics and treatment of waste water. Its products are sold and marketed under the brand names of enverdi, envital, envifa, enprint and enalyse. The company was founded by Nathalie Pautremat and Yves Dudal on February 26, 2010 and is headquartered in Montpellier, France. | Fondatore | 28/01/2010 |
INOFEA AG
INOFEA AG Packaged SoftwareTechnology Services INOFEA AG is a Swiss biotech company founded in 2014 that works closely with its clients to provide them with a complex line of services that sustain their processes and products. The company is based in Muttenz, Switzerland. The company has developed a patented platform technology called enzzen® that empowers enzymes to fit industrial applications. Enzymes are protein molecules that carry a vital energy factor needed for every chemical reaction and reactions that occur in any living organism. INOFEA has successfully demonstrated the added-value of their technology for enzyme-mediated bioconjugation or post-translational modifications of antibodies or other large molecules. Anne Timm has been the CEO of the company since 2018. | Direttore/Membro del Consiglio | - |
Perseo pharma AG
Perseo pharma AG BiotechnologyHealth Technology Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019. | Amministratore Delegato | 13/05/2019 |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Envolure SAS
Envolure SAS Medical SpecialtiesHealth Technology Envolure SAS designs, develops and commercializes laboratory kits. It offers its products for the diagnostics and treatment of waste water. Its products are sold and marketed under the brand names of enverdi, envital, envifa, enprint and enalyse. The company was founded by Nathalie Pautremat and Yves Dudal on February 26, 2010 and is headquartered in Montpellier, France. | Health Technology |
Perseo pharma AG
Perseo pharma AG BiotechnologyHealth Technology Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019. | Health Technology |
INOFEA AG
INOFEA AG Packaged SoftwareTechnology Services INOFEA AG is a Swiss biotech company founded in 2014 that works closely with its clients to provide them with a complex line of services that sustain their processes and products. The company is based in Muttenz, Switzerland. The company has developed a patented platform technology called enzzen® that empowers enzymes to fit industrial applications. Enzymes are protein molecules that carry a vital energy factor needed for every chemical reaction and reactions that occur in any living organism. INOFEA has successfully demonstrated the added-value of their technology for enzyme-mediated bioconjugation or post-translational modifications of antibodies or other large molecules. Anne Timm has been the CEO of the company since 2018. | Technology Services |
- Borsa valori
- Insiders
- Yves Dudal